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Background: In the past 20 years, society has witnessed the following landmark scientific advances: (i) the sequencing of
the human genome, (ii) the distribution of software by the open source movement, and (iii) the invention of the World
Wide Web. Together, these advances have provided a new impetus for clinical software development: developers now
translate the products of human genomic research into clinical software tools; they use open-source programs to build
them; and they use the Web to deliver them. Whilst this open-source component-based approach has undoubtedly
made clinical software development easier, clinical software projects are still hampered by problems that traditionally
accompany the software process. This study describes the development of the BOADICEA Web Application, a computer
program used by clinical geneticists to assess risks to patients with a family history of breast and ovarian cancer. The key
challenge of the BOADICEA Web Application project was to deliver a program that was safe, secure and easy for
healthcare professionals to use. We focus on the software process, problems faced, and lessons learned. Our key
objectives are: (i) to highlight key clinical software development issues; (ii) to demonstrate how software engineering
tools and techniques can facilitate clinical software development for the benefit of individuals who lack software
engineering expertise; and (iii) to provide a clinical software development case report that can be used as a basis for
discussion at the start of future projects.
Results: We developed the BOADICEA Web Application using an evolutionary software process. Our approach to Web
implementation was conservative and we used conventional software engineering tools and techniques. The principal
software development activities were: requirements, design, implementation, testing, documentation and maintenance.
The BOADICEA Web Application has now been widely adopted by clinical geneticists and researchers. BOADICEA Web
Application version 1 was released for general use in November 2007. By May 2010, we had >1200 registered users
based in the UK, USA, Canada, South America, Europe, Africa, Middle East, SE Asia, Australia and New Zealand.
Conclusions: We found that an evolutionary software process was effective when we developed the BOADICEA Web
Application. The key clinical software development issues identified during the BOADICEA Web Application project were:
software reliability, Web security, clinical data protection and user feedback.
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In the past 20 years, society has witnessed the following
landmark advances in the biological and computer sciences:
(i) the sequencing of the human genome, (ii) the develop-
ment and distribution of software by the open source
movement, and (iii) the invention of the World Wide Web.
The sequencing of the human genome [1,2] was a defining
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distribution, and reproduction in any mediumprofound implications for our understanding of the genetic
risk of disease. The work of the open source movement
may be viewed as a cultural, scientific and computing
phenomenon [3] which has had innumerable benefits for
science and society. Similarly, the invention of the Web ser-
ver [4], the implementation of Common Gateway Interface
(CGI) programs, and the widespread adoption of open
technological standards such as the Extensible Markup
Language [5] have revolutionised the distribution and pro-
cessing of digital information. Together, these advances
have provided a new impetus for clinical software (CS)
development: software developers now translate theentral Ltd. This is an Open Access article distributed under the terms of the
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use open-source programs to build them; and they use the
Web to deliver them. These activities form the basis of
many translational research projects. Whilst this open-
source component-based approach has undoubtedly made
CS development easier, CS projects are still hampered by
long-standing problems that traditionally accompany the
software process.
This study
This study describes the development of the BOADICEA
Web Application (BWA) [6], a computer program used by
clinical geneticists to assess risks to patients with a family
history of breast and ovarian cancer. The key challenge of
the BWA project was to deliver a program within an ac-
ceptable timeframe that was safe, secure and easy for
healthcare professionals to use. We focus on the BWA
software process, problems faced, and lessons learned, so
that other software developers can learn from our experi-
ence. Many problems described here are widespread in
the software industry, and so our discussion has implica-
tions for other areas of software development.
The BWA project began in January 2005. By that time,
some alternative genetic risk models had already been
implemented as desktop applications (e.g. the BRCA-
PRO and Claus models implemented in CancerGene [7],
and the Tyrer-Cuzick model implemented in IBIS [8]).
However, the BWA was the first program of its kind to
be made available on the Web.
Objectives
Our key objectives are: (i) to highlight key CS develop-
ment issues; (ii) to demonstrate how software engineering
tools and techniques can facilitate CS development for the
benefit of individuals who lack software engineering ex-
pertise; and (iii) to provide a CS development case report
that can be used as a basis for discussion at the start of
future projects.
Implementation
In this section, we describe the BOADICEA model, and
the BWA project and software process.
BOADICEA model
The Breast and Ovarian Analysis of Disease Incidence
and Carrier Estimation Algorithm (BOADICEA) [9,10]
is a risk model for familial breast and ovarian cancer.
The model can be used to compute BRCA1 and BRCA2
mutation carrier probabilities and age specific risks of
developing breast and ovarian cancer, using explicit
family history data (pedigrees), age information, cancer
diagnoses in family members, and BRCA1 and BRCA2
genetic testing information. The algorithm was devel-
oped using complex segregation analysis of breast andovarian cancer based on a combination of families iden-
tified through population based studies of breast cancer,
and families with multiple affected individuals who had
been screened for BRCA1 and BRCA2 mutations. BOA-
DICEA models the simultaneous effects of BRCA1 and
BRCA2 mutations and assumes that the residual familial
clustering of breast cancer is explained by a polygenic
component (a large number of genes each of small ef-
fect), with a variance that decreases linearly with age.
Individuals are assumed to follow calendar period and
cohort specific incidence rates for breast and ovarian
cancer. The BOADICEA model has been assessed [11]
using data from UK genetics clinics and has been found
to be well calibrated within these families and to
discriminate well between BRCA1, BRCA2 and non-
mutation carriers.
BOADICEA Web Application project
BOADICEA was originally implemented as a standalone
Fortran program (termed here the BOADICEA core pro-
gram, BCP). The BCP has been used by scientists for
some years as a research tool. However, in practice,
computing risks with the BCP was difficult and time
consuming, which made it inappropriate for use in a
clinical setting. To address this problem, we developed
the BWA, a user-friendly Web interface to the BCP
which has greatly simplified this process. BWA v1 was
released for general use 2 years and 10 months after the
start of the project. The BWA project milestones were
as follows: (i) BWA project begins (January 2005); (ii)
BWA v1 trial software released for evaluation and testing
(January 2007); (iii) BWA v1 released for general use
(November 2007); (iv) BWA v2 trial software released
for evaluation and testing (November 2009); and (v)
BWA v2 released for general use (August 2010). This
work took longer than anticipated, but there were im-
portant mitigating factors: (i) none of our team had any
prior experience of CS development for the Web; (ii)
our list of requirements was substantial (see Require-
ments section below); and (iii) the development of the
online pedigree building module was particularly diffi-
cult and time consuming (see Design section below).
Software process
We developed the BWA using an evolutionary software
process (Figure 1). Our approach to Web implementation
was conservative and we used conventional software en-
gineering tools and techniques. We did not conform
strictly to an established software process model. However,
the BWA software process was iterative and program
modules were delivered in increments, and so there were
similarities with the incremental process model (e.g. Press-
man [12]). The principal software development activities
were: requirements, design, implementation, testing,
Requirements Design Implementation Testing
Documentation
Final Version Release
BWA v1 
Design updates/Defect fixes
Trial Version Release
Testing
BWA software process
User Evaluations
Final Defect Fixes Maintenance
Requirements DesignBWA v2 
Software reliability
Key clinical software development issues  
Milestone (i) Jan 2005
Milestone (ii) Jan 2007
Milestone (iii) Nov 2007
Web security Clinical data protection User feedback
Figure 1 BOADICEA Web Application software process. This flowchart shows the main activities in the BWA software process described in
the text (project milestones are labelled). The key clinical software development issues identified during the project are listed at the bottom of
the figure.
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described below.
Requirements
At the start of the BWA project, we established the
functional requirements of the program. In particular,
the program would enable the user to: (i) build new
pedigree data sets quickly and flexibly online; (ii) upload
pre-existing pedigree data sets; (iii) review the pedigree
data set in a table and drawing; (iv) compute BRCA1
and BRCA2 mutation carrier probabilities and breast/
ovarian cancer risks; (v) view the computed results in
data tables; and (vi) download the input pedigree data
set and computed results in plain text and PDF format.
These requirements were set out in a software require-
ments specification document with mock-ups of the
Web interface.
The software requirements specification document
ensured that requirements were properly understood,
and that problematic design issues were considered from
the outset. Clinical geneticists were involved in therequirements process from the start of the BWA project.
Their advice helped to ensure as far as possible that the
program would be easy to use in a clinical setting. We
believe that the involvement of end users in the require-
ments process was key to the success of the project.
Owing to the complexity of the proposed software, we
could not anticipate all program behaviours at the
outset. As a result, Web interface designs evolved sub-
stantially as the project progressed. Since the release of
BWA v1, software development has been driven by two
further ongoing requirements: (i) the need to accommo-
date extensions to the BOADICEA model; and (ii) the
need to implement suggestions for improvement made
by users.
Design
Our main objectives were to design a Web interface that
would: (i) have a look and feel that would seem familiar
to clinical geneticists; (ii) make risk calculations quick
and easy; (iii) reduce data errors by constraining user
inputs; (iv) function intuitively and respond intelligently
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have unambiguous data prompts; (vii) minimise key
strokes and enable users to set defaults automatically;
and (viii) help clinical geneticists to communicate results
to patients (e.g. by providing a processing report PDF).
The Web interface was also designed to process cached
Web pages intelligently.
Our original aim was to design a Web interface that
would make BOADICEA easy to use for clinical geneti-
cists, researchers and members of the public. However,
these individuals represented a wide spectrum of users
with differing prior knowledge and expertise. As a result,
we found it difficult to design a Web interface that could
accommodate the diverse needs of all these different
user groups. One alternative would have been to imple-
ment different modes of operation e.g. ‘clinician mode’
and ‘public mode’. Patients could have used a simplified
‘public mode’ interface to build a preliminary pedigree
data set prior to a consultation with a clinical geneticist.
This would have helped to shift some of the burden of
data entry from the counsellor to the counselee. How-
ever, time and funding constraints prevented us from
designing two separate modes of operation. As a result,
our main aim was to design a program that would be
easy to use in a clinical setting.
The online pedigree building module was intended to
enable users to build pedigrees quickly and easily. How-
ever, in practice, the module delivered with BWA v1 was
difficult and time consuming to use. This problem was
principally one of Web interface design. Work on this
module was problematic because: (i) it included pedigree
building functions that were previously unavailable in
comparable Web-based programs, and so required a
novel design solution; and (ii) we were hampered in this
task by our lack of prior Web programming experience.
After further development, the pedigree building module
delivered with BWA v2 did fulfil all initial requirements.
This was made possible by refinements to the design of
the interface. Our experience of this task was consistent
with the observation that ‘the incompletenesses and
inconsistencies of our ideas become clear only during
implementation’ [13], or that ‘you often don’t really
understand the problem until after the first time you im-
plement a solution’ [3].
Implementation
The BCP had been implemented in Fortran prior to the
start of the BWA project. We chose to implement the
BWA CGI module in Perl for the following reasons: (i)
Perl was a de facto language for CGI programming; (ii)
the CGI.pm module [14] and Perl regular expressions
would make handling Web form data easier; (iii) Perl
text processing functions could be used to create and
manipulate the many data files required by the BCP; (iv)Perl could be used to run all necessary external pro-
grams and to implement separate software installation
and backup scripts; (v) Perl taint mode would help to
make the program more secure; and (vi) the Compre-
hensive Perl Archive Network [15] would provide nu-
merous open-source modules to interface with databases
and other software. In addition, we used JavaScript to
control Web page behaviours and to validate Web form
parameters in the user’s browser.
We also made extensive use of open-source technolo-
gies including the Linux operating system, Apache Web
server, MySQL database, Perl interpreter, gfortran com-
piler, R statistical computing package, Kinship pedigree
drawing package, ImageMagick image processing pack-
age, html2ps document converter, Concurrent Versions
System version control package and Xemacs program-
ming editor.
We used a bottom-up development scheme: we devel-
oped low level modules first, and then combined them to
form higher level ones. We also used the following defen-
sive programming techniques [16]: (i) we used assertions;
(ii) we checked the values of input from external sources;
(iii) we handled exceptions gracefully; (iv) we implemented
subroutines with low coupling to try to contain the dam-
age caused by errors; and (v) we checked function return
values. The source code included hundreds of assertions
to check for data processing errors. When an assertion
failed during program execution, we modified the code to
ensure that it would not fail again in the same way. The
assertions also made it easier to identify new defects intro-
duced during source code modifications.
When we implemented the BWA, our aim was to
write source code that was stable, reliable, maintainable
and extensible. We attempted to write source code that
could be easily understood by others, as this helped to
make clear both the behaviour of the program and the
underlying intentions of the programmer. At the start of
the project, we established in-house coding conventions
according to good practice [16] and enforced them.
Wherever possible, source codes were broken into cohe-
sive modules and stored in libraries. For clarity, we tried
to separate JavaScript and HTML as far as possible.
Testing
The aim of software testing was to find and eliminate
defects (faults that failed on execution). Before the BWA
was released, we ran an initial set of in-house tests and
applied defect fixes and design updates on the basis of
the test results. This process was iterative. After these
initial tests, we wrote the accompanying documentation
and released the BWA v1 trial software for evaluation by
users (users were informed of its trial status). During
this period of evaluation, we ran a further set of in-
house tests. Once this further phase of in-house testing
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fixes, we released BWA v1 for general use.
In-house software tests were planned and executed
systematically, and test results were documented. We
prioritised tests to exercise modules that had the potential
to generate the most harmful defects. Test cases were
designed to uncover specific classes of defect, and to
ensure that data were displayed consistently. The most
serious defects were uncovered by in-house tests. Some of
these defects were due to simple semantic errors, or to
errors of omission. This observation is sobering. However,
we found that software faults could be easily overlooked
when the program included several tens of thousands of
lines of source code.
We considered software reliability to be the most im-
portant issue in BWA development. Consequently,
nearly 30% of our development time was devoted to test-
ing. We found that in-house tests and user evaluations
were complementary as these activities were based on
internal and external views of the program respectively.
During the software evaluations, users provided essential
feedback. As users developed a better understanding of
the program, so we developed a better understanding of
how they were using it. In this way, user feedback
formed a vital part of the software process. Nevertheless,
in spite of this, we recognised that users could only
identify a subset of defects as: (i) user evaluations were
not systematic; and (ii) users were only likely to identify
a defect if a computed result (or software behaviour) dif-
fered significantly from their own expectation.
Documentation
BWA documentation consisted of the user guide [17] and
frequently asked questions on the project Web site [6].
The user guide provided simple instructions on the use of
the program, and described limitations of the BOADICEA
model and key input data requirements. We always asked
users to read the user guide before they used the program,
but we had to accept that some individuals may not have
had time to do so. The Cambridge University Legal
Services Department also drafted a software license agree-
ment that set out our terms of use.
Maintenance
The principal aims of software maintenance were to
implement defect fixes and enhancements to the BWA,
and to support the BWA user community. Web deploy-
ment made some maintenance tasks easier because: (i)
we could update program executables on the server eas-
ily; (ii) we did not have to maintain different software
builds for different operating systems; and (iii) we could
log user activity on the server.
The installation of the BWA v2 trial software revealed
a potential software maintenance pitfall. To implementthis new software, we had to upgrade several open-
source components (e.g. Perl, R and MySQL). However,
we found that some of these updated components were
incompatible with BWA v1. At that time, we already had
>900 users, and it was essential that these upgrades did
not cause an interruption to service. To address this
problem, we setup a separate Linux test server and ran a
trial software installation to ensure that both BWA v1
and v2 worked together with the updated components.
Once we had resolved the incompatibilities and the trial
software installation was successful, we could then per-
form the same installation on our production server
without problems.
Results
System description
Clinical geneticists use the BWA to calculate BRCA1 and
BRCA2 mutation carrier probabilities and breast/ovarian
cancer risks. These data are used to determine eligibility
for genetic testing or to identify individuals at high risk of
developing breast/ovarian cancer who can then be offered
individually tailored clinical management. BWA v1 was
released for general use in November 2007. By May 2010,
we had >1200 registered users based in the UK, USA,
Canada, South America, Europe, Africa, Middle East, SE
Asia, Australia and New Zealand. Figure 2 shows the
number of concurrent BWA sessions logged on the server
during the week of the 17th May 2010. BWA users
included clinical geneticists, researchers and members of
the public.
Online workflow
To compute risks, users negotiate a simple online work-
flow (Figure 3). First, the user must supply an input
pedigree data set. The user can either: (i) build a new
pedigree data set online, or (ii) upload a pre-existing
pedigree data set for processing. All clinical data are
transmitted across an encrypted Web connection.
To build a new pedigree data set online, the user first
supplies details of the consultand and the consultand’s
parents on three ‘Family Member’ Web pages (Figure 4a).
Once these details have been submitted, the program
returns a ‘Pedigree Table View’ Web page (Figure 4b) list-
ing these individuals in a table. The user can then use
pedigree editing functions to add additional relatives, and
to update individual data parameters.
Users can also upload a pre-existing pedigree data set
for processing. To do this, the user must first create a
pedigree data file in the BOADICEA import/export
digital data format (a simple plain text format designed
to facilitate pedigree data exchange, described in Appen-
dix A of the user guide [17]). Some commercial pedigree
data management/drawing programs such as Progeny
[18], Clinical Pedigree [19] and PED [20] now include a
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Figure 2 BOADICEA Web Application server activity logged during the week of the 17th May 2010. This curve shows the number of
concurrent BWA sessions initiated on the server by users of BWA v1 and v2 trial software. The prominent peaks in the curve correspond to peak
user activity during weekday evenings. Times plotted as the independent variable were recorded during British Summer Time.
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widen access to BOADICEA further.
When the input pedigree data set is complete, the user
can review it prior to running a risk calculation. The
‘Pedigree Table View’ Web page (Figure 4b) lists details
of all family members in a data table. Similarly, the user
can draw the pedigree using the Kinship package [21]
implemented in the R environment [22] (Figure 4c).
Once the input pedigree data set has been finalised, the
user can compute risks at the push of a button. The BWA
returns BRCA1 and BRCA2 mutation carrier probabilities
and age specific breast/ovarian cancer risks in a ‘Com-
puted Results’ Web page (Figure 4d). The user can also
adjust key model data parameters such as the population
BRCA1 and BRCA2 mutation frequencies and mutationReview pedigree in data
Compute BRCA1 and BRCA2 mutation carrier p
Build a new pedigree online
Download the input pedigree and re
Delete all data files created durin
Logo
Figure 3 BOADICEA Web Application workflow. This flowchart shows thsearch sensitivities, so that the risk calculation can be tai-
lored to different populations and genetic testing methods.
Once BOADICEA risks have been computed, the user
can download the input pedigree data set and results in
a plain text data file and processing report PDF. The
PDF is intended to help genetic counsellors communi-
cate risks to patients. Whilst the PDF includes tables of
BRCA1 and BRCA2 mutation carrier probabilities and
breast/ovarian cancer risks, the presentation of these
data could be refined to facilitate communication further
(e.g. breast and ovarian cancer risks could be plotted on
a graph with equivalent population risks to aid their in-
terpretation in a wider context). Ongoing research pro-
jects aimed at communicating risks effectively will
inform further improvement of risk reporting.Upload a pre-existing pedigree
 table and drawing
robabilities and breast/ovarian cancer risks
sults in plain text and PDF format
g the session from the server
ut
e main processing steps in the online workflow described in the text.
Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 (a) Family Member Web page. Family Member Web pages are used to capture details of individual family members within the
pedigree (in this case the consultand). Users are prompted for details of sex, vital status, Ashkenazi Jewish origin, age or age at death (age at last
follow up), year of birth, cancer history and genetic status. Family Member Web pages have been designed so that users can input data quickly
and easily. JavaScript functions control the behaviour of the input elements so that the Web page functions intuitively and responds intelligently
to user inputs. JavaScript functions are also used to validate input data parameters when the Web page is submitted for processing. All data
validations run on the Web page are repeated on the server for security purposes. (b) Pedigree Table View Web page. The Pedigree Table
View Web page is used to display the tabulated input pedigree data set. Each table row includes details of a single family member, and each
table column corresponds to a specific input data parameter. The Web page includes two rows of function buttons: the top row functions are
used to navigate the table and edit the pedigree; the bottom row functions include functions to logout or reset the current session, to update
BOADICEA model parameters, to draw the pedigree, to switch the target (index or subject of the risk calculation) and to compute risks. The
target is highlighted in the table with a grey table row. (c) Pedigree drawing. Pedigree drawing generated using the Kinship package [21]
implemented in the R environment [22]. The pedigree drawings are annotated in the conventional manner: the target is identified with an arrow,
and family members who have developed cancer are shaded. The text annotation beneath each family member includes the following
parameters: unique identifier, first name/ID and age or age at death (age at last follow up), year of birth, cancer history and genetic status. (d)
Computed Results Web page. The Computed Results Web page lists BRCA1 and BRCA2 mutation carrier probabilities and breast/ovarian cancer
risks computed by BOADICEA from the input pedigree data set (expressed as decimal probabilities). BRCA1 and BRCA2 mutation carrier
probabilities are shown in the top left-hand table, and breast/ovarian cancer risks are shown in the right-hand table. The bottom left-hand table
shows the BOADICEA model parameters used in the calculation.
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cally ensures that it can be updated at a later date [23].
Early in the BWA project, we considered the possibility
of storing pedigree data sets on the BWA system. This
would have enabled users to access their data from any
location which would have made the program easier to
use. However, this solution would also have conflicted
with our requirement to conform to data protection
principles (described in the Clinical data protection sec-
tion below). Hence, the existing data storage solution
may be viewed as a compromise intended to meet com-
peting requirements for software usability and clinical
data protection. When the user logs out, all data files
created during the session are deleted from the server.
Alternatively, if the user does not log out, the data files
will be deleted after a period of 24 hours when the ses-
sion times out.
The BWA has now made it much easier for clinical
geneticists to run BOADICEA risk calculations in a clin-
ical setting. As we develop the BWA further, we hope to
achieve a better integration between the program and
the wider genetic counselling workflow.
Discussion
We found that an evolutionary software process was ef-
fective when we developed the BWA. The key CS devel-
opment issues identified during the BWA project were:
software reliability, Web security, clinical data protection
and user feedback. These issues are described below.
Key clinical software development issues
Software reliability
In our view, software reliability is the most important
issue in CS development. Clinical geneticists use the
BWA to calculate BRCA1 and BRCA2 mutation carrier
probabilities and breast/ovarian cancer risks, which areused to determine eligibility for genetic testing or to pro-
vide individually tailored clinical management. As a re-
sult, defects in the program could have implications for
the management of patients.
Software defects cause programs to function unreli-
ably. Testing can help to find defects in substantial com-
puter programs, but it is impossible to eliminate them
completely (e.g. Myers [24] noted that ‘in general, it is
impractical, often impossible, to find all the errors in a
program’). Hence, we have to accept that some defects
are likely to remain undetected. McConnell [16] sug-
gested that the ‘industry average is about 15 to 50 errors
per 1000 lines of code for delivered software’. BWA v1
included approximately 40000 lines of code. Conse-
quently, we took steps to ensure as far as possible that
the program functioned reliably before it was released
for general use. In-house tests revealed the most serious
defects. Less serious defects were reported by users dur-
ing the software evaluations. As part of the software
process, we enforced in-house coding rules and used de-
fensive programming techniques [16]. We believe that
these measures helped to prevent the introduction of
faults and to make the software more reliable.
Web security
Web security is an additional challenge in CS develop-
ment. All computers connected to the Internet are at
risk of malicious attack, and Web servers running CGI
applications are particularly vulnerable [25]. Conse-
quently, we took steps to minimise the effects of a mali-
cious attack should one occur. To help secure the BWA
server, we ensured that: (i) clinical data were always
stored outside the document root; (ii) appropriate per-
missions were set on program files; (iii) a firewall was in
place; (iv) the operating system was patched; (v) non-
essential services were shutdown; (vi) data transmissions
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the server before use; (viii) Perl components ran in taint
mode; and (ix) computers that were detected probing
the server were subject to access restrictions with Fail2-
ban [26]. The Cambridge University Computing Service
also probed the server periodically to try to identify se-
curity vulnerabilities.
Clinical data protection
Clinical data protection is a further key issue in CS de-
velopment. If healthcare professionals believe that a
Web-based program may put patient data at risk, they
will not use it. As a result, we took steps to conform as
far as possible to the data protection principles set out
in Schedule one to the Data Protection Act 1998 [27]: (i)
the program does not use data items that are regarded
as strong patient identifiers [28] (in particular, the pro-
gram does not use full name [only first name is used
which is optional], address, date of birth, postcode, NHS
number or local patient identifier); (ii) we collected only
the minimum data required to enable users to compute
and interpret risks; and (iii) data were deleted when the
user logged out, or after a period of 24 hours when the
session timed out.
It is important to consider whether the identity of an
individual could be inferred from the data submitted by
users. The BWA prompts for only three of the 14 key
items of patient-identifiable information set out in Ap-
pendix 7 of the Caldicott Committee Report [29]: fore-
name (which is optional), sex and ethnic group. The
Caldicott Committee Report states that ‘an individual
item from this list, taken with another item from a par-
ticular flow, may in certain circumstances enable identity
to be inferred’, and it gives as an example ‘age linked to a
diagnosis’. Since BWA users supply details of age and
cancer diagnosis, it may be possible to infer an indivi-
dual’s identity from these data, or possibly from other
combinations of data. However, in practice, the ease with
which this can be accomplished depends on the nature
of the data items and the context of their disclosure.
We also configured the BWA so that a user could only
view data submitted during his/her current session. As a
result, if for example an unauthorised person were to
use John Smith’s username and password to access the
system, then any data sets submitted concurrently by
John Smith would still be inaccessible to the unauthor-
ised person, as they would be stored elsewhere.
User feedback
As soon as we released the BWA v1 trial software, we urged
users to report computed results or software behaviours
that differed significantly from their own expectation.
Whenever a user queried a result, we first attempted to rep-
licate their result using the BCP alone to determinewhether the problem was associated with the BCP or the
Web interface (results generated with the BCP had been
compared with data from UK genetics clinics [11], but we
were aware that the BCP could still include defects). We
then sought to explain why the user’s result failed to meet
expectation. In most cases, users reported problems: (i)
when the BOADICEA model behaved in a way that was
unexpected to them (e.g. users were sometimes surprised
by the effect that different mutation search sensitivities had
on computed risks); and (ii) when key input data para-
meters were excluded unintentionally from the risk calcula-
tion. As a result, we learned that it was important to inform
users of some specific BOADICEA model behaviours and
key input data requirements. In this way, user inquiries
formed the basis of many frequently asked questions on the
project Web site [6]. By verifying user results, we gained
further confidence that the BWA was functioning reliably.
Conclusions
The BWA has now been widely adopted by clinical
geneticists and researchers. Key observations and lessons
learned during the BWA project were as follows:
1. We found that an evolutionary software process was
effective when we developed the BWA. Our
approach to Web implementation was conservative
and we used conventional software engineering tools
and techniques. The software process had to be
sufficiently flexible to accommodate evolving Web
interface designs. The key CS development issues
identified during the BWA project were: software
reliability, Web security, clinical data protection and
user feedback.
2. The software requirements specification document
ensured that requirements were properly
understood, and that problematic design issues were
considered from the outset.
3. We were unable to design a Web interface that
would fully accommodate the diverse needs of
clinical geneticists, researchers and members of the
public. Our main aim was to design a program that
would be easy to use in a clinical setting.
4. We had to devise a novel design solution for the
online pedigree building module.
5. We implemented the BWA CGI module in Perl and
made extensive use of open-source technologies.
6. In-house software tests were planned and executed
systematically, and test results were documented.
We prioritised tests to exercise modules that had
the potential to generate the most harmful defects.
The most serious defects were uncovered by in-
house tests.
7. In our view, software reliability was the most
important issue in CS development. Software testing
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some defects were likely to remain undetected.
8. We took the following steps to improve software
reliability: (i) we enforced in-house coding rules; (ii)
we used defensive programming techniques; (iii) we
tested the software extensively; and (iv) we urged
users to report computed results and software
behaviours that differed substantially from their own
expectation.
9. We found that in-house tests and user evaluations
were complementary as these activities were based
on internal and external views of the program
respectively. As users developed a better
understanding of the program, so we developed a
better understanding of how they were using it.
10.We took steps to minimise the effect of a malicious
attack on the BWA server should one occur.
11.We took steps to conform as far as possible to the
data protection principles set out in Schedule one to
the Data Protection Act 1998.
12.We learned that it was important to inform users of
some specific BOADICEA model behaviours and
key input data requirements.
13.User feedback was extremely important to us and it
helped to shape the software process. User inquiries
formed the basis of many frequently asked questions
on the project Web site. By verifying computed
results queried by users, we gained further
confidence that the BWA was functioning reliably.
Availability and requirements
Project name: BOADICEA
Project home page: [http://www.srl.cam.ac.uk/genepi/
boadicea/boadicea_home.html]
Operating system: The BWA is implemented on an
Ubuntu Linux computer. Users access the software via
the Web.
Programming language: The BWA is implemented in
Perl and JavaScript, and the BCP is implemented in
Fortran.
Other requirements: Modern Web browser with active
scripting enabled
License: [http://www.srl.cam.ac.uk/genepi/boadicea/BWA_
v2_Software_and_Data_Processing_Agreement.pdf]
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